Filing Details
- Accession Number:
- 0000921895-20-002827
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-06 18:30:18
- Reporting Period:
- 2020-11-04
- Accepted Time:
- 2020-11-06 18:30:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1175505 | Five Prime Therapeutics Inc. | FPRX | Investment Advice (6282) | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 918923 | P L Fund Value Biotechnology | 44 Montgomery Street 40Th Fl San Francisco CA 94104 | No | No | Yes | No | |
| 1055947 | P/Il L Partners Bvf | 44 Montgomery St. 40Th Fl San Francisco CA 94104 | No | No | Yes | No | |
| 1056807 | Bvf Inc/Il | 44 Montgomery Street 40Th Fl San Francisco CA 94104 | No | No | Yes | No | |
| 1102444 | Biotechnology Value Fund Ii Lp | 44 Montgomery Street 40Th Fl San Francisco CA 94104 | No | No | No | Yes | |
| 1233840 | N Mark Lampert | 44 Montgomery Street 40Th Fl San Francisco CA 94104 | No | No | Yes | No | |
| 1660683 | Biotechnology Value Trading Fund Os Lp | P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104 | No | No | No | Yes | |
| 1660684 | Ltd. Os Partners Bvf | P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104 | No | No | No | Yes | |
| 1803805 | Bvf I Gp Llc | 44 Montgomery St., 40Th Floor San Francisco CA 94104 | No | No | Yes | No | |
| 1803806 | Bvf Ii Gp Llc | 44 Montgomery St., 40Th Floor San Francisco CA 94104 | No | No | No | Yes | |
| 1803809 | Bvf Gp Holdings Llc | 44 Montgomery St., 40Th Floor San Francisco CA 94104 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 Par Value | Acquisiton | 2020-11-04 | 257,804 | $4.88 | 4,594,679 | No | 4 | P | Direct | |
| Common Stock, $0.001 Par Value | Acquisiton | 2020-11-06 | 17,230 | $4.98 | 4,611,909 | No | 4 | P | Direct | |
| Common Stock, $0.001 Par Value | Acquisiton | 2020-11-04 | 143,403 | $4.88 | 3,424,554 | No | 4 | P | Direct | |
| Common Stock, $0.001 Par Value | Acquisiton | 2020-11-06 | 10,436 | $4.98 | 3,434,990 | No | 4 | P | Direct | |
| Common Stock, $0.001 Par Value | Acquisiton | 2020-11-04 | 15,355 | $4.88 | 581,578 | No | 4 | P | Direct | |
| Common Stock, $0.001 Par Value | Acquisiton | 2020-11-06 | 2,334 | $4.98 | 583,912 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct |
Footnotes
- This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
Billionaire Hedge Funds
